On a relative basis, the stock has outperformed the S&P 500 by 2.22% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.47% in the last 1 week, and is up 6.69% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 3.41% and the 50-Day Moving Average is 6.17%.
Merck & Company (NYSE:MRK): The stock opened at $59.80 on Friday but the bulls could not build on the opening and the stock topped out at $59.93 for the day. The stock traded down to $59.25 during the day, due to lack of any buying support eventually closed down at $59.63 with a loss of -0.03% for the day. The stock had closed at $59.65 on the previous day. The total traded volume was 8,162,693 shares.
The company Insiders own 0.05% of Merck & Company shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -30.73% . Institutional Investors own 74.29% of Merck & Company shares. During last six month period, the net percent change held by insiders has seen a change of -30.73%. In a related news, The officer (Exe V-P, HR), of Merck & Co., Inc., Graddick Weir Mirian M had unloaded 45,000 shares at $57.96 per share in a transaction on July 5, 2016. The total value of transaction was $2,608,200. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.